Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IR199
- Development stage
- Phase 1
- Lead developer
- Huashan Hospital
- Modality
- Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
IR199 is a radiopharmaceutical targeting Claudin 18.2 (CLDN18.2), a tight junction protein frequently overexpressed in gastric and pancreatic adenocarcinomas. It is being developed as a theranostic agent, utilizing Gallium-68 ([68Ga]) for positron emission tomography (PET) imaging to assess biodistribution and tumor uptake, and Iodine-131 ([131I]) for dosimetry and potentially targeted radionuclide therapy. The agent is currently in early-phase clinical trials to evaluate its safety and imaging characteristics in patients with CLDN18.2-positive gastrointestinal cancers.
- Other names
- [68Ga]-IR199[131I]-IR199[68Ga]/[131I]-IR199
02
Targets
Claudin 18.2
Beyond the preview
Go deeper on IR199.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IR199.